Palisade Bio, Inc. (PALI) vs Sutro Biopharma, Inc. (STRO)

Palisade Bio, Inc. and Sutro Biopharma, Inc. are both Biotechnology companies. Palisade Bio, Inc. and Sutro Biopharma, Inc. are of similar size ($273.6M and $260.5M). Sutro Biopharma, Inc. has negative trailing earnings, so its P/E is not meaningful; Palisade Bio, Inc. trades at 2.2×. Palisade Bio, Inc. grew revenue faster over the last twelve months: 5,492.6% against −56.3%. Sutro Biopharma, Inc. has the higher net margin (−395.3% vs −4,230.6%) and the higher return on invested capital (0.00% vs 0.00%). Across the 15 metrics below, Sutro Biopharma, Inc. leads on 8 and Palisade Bio, Inc. on 7.

Valuation

Metric PALI STRO Biotechnology median
P/E 2.24 n/m 7.88
P/S 405.97 5.79 11.47
P/B 2.52 n/m 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales 240.84 2.83 10.73
Earnings yield 44.66% (108.41%) (28.84%)
Free cash flow yield (5.94%) (54.99%) (23.03%)

Profitability

Metric PALI STRO Biotechnology median
Gross margin 95.63% 100.00% 65.16%
Operating margin (4,681.99%) (319.57%) 0.00%
Net margin (4,230.60%) (395.25%) 0.00%
Free cash flow margin (2,409.27%) (318.63%) 0.00%
Return on equity (51.37%) 266.76% (57.72%)
Return on assets (47.68%) (79.08%) (49.22%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric PALI STRO Biotechnology median
Revenue growth (TTM) 5,492.59% (56.25%) 5.64%
EPS growth (last fiscal year) 97.06% 24.02% —
Revenue growth, 5-year CAGR 72.86% 19.12% 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric PALI STRO Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 24.26 3.32 4.73
Net debt to EBITDA 7.37 0.92 0.96

Dividend

Metric PALI STRO Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric PALI STRO Biotechnology median
Market cap 273.60m 260.49m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack